key: cord-0754797-fprlymol authors: Tissières, Pierre; Teboul, Jean-Louis title: SARS-CoV-2 post-infective myocarditis: the tip of COVID-19 immune complications? date: 2020-07-23 journal: Ann Intensive Care DOI: 10.1186/s13613-020-00717-0 sha: 837888b2871e67247b1b6753db746ee7889f4a87 doc_id: 754797 cord_uid: fprlymol Recent paediatric cases of acute myocarditis following a SARS-CoV-2 infection have raised the possibility of post-infective complications of COVID-19. This short editorial is reviewing current understanding of this new complication, its pathophysiology, diagnosis and therapeutic strategy. Recent descriptions of a short outbreak of acute myocarditis in otherwise healthy children raise the hypothesis of additional critical complications of SARS-CoV-2 infection [1] [2] [3] [4] [5] [6] . Grimaud et al. just reported in Annals of Intensive Care, a series of 20 critically ill children with shock admitted, during a 12-day period, in four pediatric intensive care units in the Paris urban area [1] . This outbreak occurred after 4-6 weeks of strict lockdown. All children had acute myocardial dysfunction requiring cardiovascular support. This study confirmed similar observations from United Kingdom, France and Switzerland [2] [3] [4] [5] [6] . In the Grimaud et al. study, 19 out of 20 children had either positive SARS-CoV-2 detection by quantitative PCR or positive serology. The remaining child had a typical SARS-CoV-2 chest tomography scan. Note that all children had abdominal symptoms [1] . Acute heart failure is clearly a dissonant clinical feature of COVID-19 infection in children that is known to be less frequent and less severe than in adults and with very low mortality [7, 8] . Besides its unusual nature, the main characteristic of COVID-19 acute myocarditis is its association with major multisystem inflammatory syndrome, mimicking a well-known pediatric entity, the Kawasaki disease. Currently three case definitions issued from the World Health Organization, the Centers for Disease Control and Prevention and the Royal College of Paediatrics and Child Health related to this emerging inflammatory condition during COVID-19 pandemic exist. Those definitions identify the multisystem inflammatory syndrome in children (MIS-C) or the Pediatric Inflammatory Multisystem Syndrome (PIMS) [4] . All three case definitions include either partial or full criteria for Kawasaki disease and evidence of COVID-19 diagnosis (clinical and/or biological-serology/PCR). Kawasaki disease's, which affect mostly young children of less than 5 years of age, has typical clinical features including: (1) prolonged fever, (2) conjunctivitis, (3) dry cracked lips, ((4) cervical adenopathy (5) diffuse skin rash involving the trunk and extremities, subsequent desquamation of the tips of the toes and fingers, and 6) edema. In addition to classical manifestations of Kawasaki disease, MIS-C patients, who are much older, display digestive symptoms, shock and myocardial involvement more frequently [9] . Kawasaki disease pathophysiology refers to a systemic arteritis with the most severe complication being coronary aneurysm. Kawasaki disease can follow by a few days or weeks a wide range of infection involving numerous viruses such as EBV, MERS-and SARS-CoV-1, H1N1 influenza and other respiratory illnesses [10] . Analogy of the COVID-19 post-infective acute myocarditis with the Kawasaki Disease Shock Syndrome does not only result from a pediatric cognitive bias, but also from a well-described pathophysiology of systemic arteritis seen in the Kawasaki disease. Neutrophils, especially CD14+ CD16+ cells have been identified in arterial wall early in the disease followed by dendritic cells, CD163+ monocytes/macrophages, cytotoxic CD8+ T cells and CD3+ T cells infiltration and subsequent massive production of chemokines and cytokines, especially IL-1 and IL-6. Similarly to the Kawasaki disease, COVID-19 is recognized as a systemic vasculitis affecting not only the lung but all organs, such as the myocardium [11, 12] . How the COVID-19 histopathognomic signature, systemic microangiopathy and thrombosis can be connected to the overt cytokine release and immune cells tissue infiltration seen in the Kawasaki disease? Again, neutrophils infiltration offers a convincing connection. Recent insight on the role of neutrophils capacity to form extracellular traps (NETs) to ensnare pathogens and limit extension of infection was evidenced in severe COVID-19, similarly to what was reported in acute Kawasaki disease [13] . An important trigger of the Kawasaki disease is the development of immune complexes in the circulation. These immune complexes interact with their cellular receptors-the Fcγ receptors-expressed on macrophages, dendritic cells, neutrophils and platelets promoting phagocytosis, degranulation and respiratory burst. In addition, immune complexes can precipitate in tissue leading to local inflammation, complement activation, and organ dysfunction. In contrast to the Kawasaki disease, the role of post-infective immune complexes has not yet been demonstrated in COVID-19 patients [10] , but published data strongly suggest a COVID-19 Table 1 What is known and how to further proceed with COVID-19 post-infective myocarditis? SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; CRP, C-reactive protein; BNP, brain natriuretic peptide; cluster of differentiation-8; IL-6, interleukin 6; COVID-19, coronavirus infection disease 2019; Ig, immunoglobulins; CD8, cluster of differentiation 8; IVIg, intravenous immunoglobulins a Autopsy and endomyocardial biopsy findings are issued from COVID-19 patients [7, 8] What is known? What need to be clarified? Controlled trials comparing hemodynamic tolerance of IVIg and IL-1 receptor antagonist is warranted IL-1 receptor antagonist Limited experience suggests that use of Anakinra is well tolerated and clinical response rapid. It may be an alternative to IVIg in depressed myocardial function or in addition if symptoms are refractory to IVIg [1, 2] post-infective component [1, 2] . In the published pediatric series [1] [2] [3] [4] [5] [6] , patients with acute myocarditis had either a SARS-CoV-2 detection or positive serology with IgG present in the great majority, while no other causes of myocarditis were identified. The expected SARS-CoV-2 antibody response is first an increase in immunoglobulin M, immediately followed by immunoglobulin G with a peak between 17 and 22 days after symptoms onset. By analogy to Kawasaki disease, we cannot exclude that formation of immune complexes play a role in the development of COVID-19 myocarditis. In the published series [1] [2] [3] [4] [5] [6] , most children with COVID-19 post-infective acute myocarditis were successfully treated with intravenous immunoglobulins and aspirin, similarly to what is recommended for the Kawasaki disease [1] [2] [3] [4] [5] [6] . Immunomodulatory effects of immunoglobulins are well described and known to dampen hyperinflammation, and attenuate the immune complex-mediated response seen in patients with Kawasaki disease [10] . Anti-inflammatory dose of aspirin is used in the first 15 days, and then continued at an anti-aggregative regimen for 2 months if coronary arteries failed to show aneurysm. No patients had coronarography as in Kawasaki disease aneurysm are rare and usually occurs in the first coronary segment which is easily assessed by echocardiography or coronary scan. Interestingly, few patients with COVID-19 post-infective myocarditis with incomplete response immunoglobulins received subsequently IL-1 receptor antagonist (Anakinra) therapy and were eventually cured [1, 2] . Targeting IL-1 pathway, especially with massive inflammation, could emerge as a potential therapy in severe COVID-19 patients [14] . Although many clinical similarities exist with Kawasaki disease, COVID-19 post-infective myocarditis should be considered as a potential complication of COVID-19 that may not be limited to children. We cannot exclude that during the SARS-CoV-2 pandemic, some adult patients with isolated or predominant acute heart failure and negative SARS-CoV-2 PCR would have experienced a post-infective complication of COVID-19. Systematic serology in such a context could help in diagnosing this complication. Current knowledge on Kawasaki disease and the numerous similarities between both clinical entities may help us in establishing research hypothesis ( Table 1) . Probability of facing the emergence of COVID-19 post-infective complications is high, and the occurrence of post-infective acute myocarditis outbreak urges us to set a systematic clinical, biological and echocardiographic follow-up of all patients who developed COVID-19. Acute myocarditis and multisystem inflammatory emerging disease following SARS-CoV-2 infection in critically ill children Acute heart failure in multisystem inflammatory syndrome in children (MIS-C) in the context of global SARS-CoV-2 pandemic Hyperinflammatory shock in children during COVID-19 pandemic Clinical characteristics of 58 children with a pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 Paediatric inflammatory multisystem syndrome: temporally associated with SARS-CoV-2 (PIMS-TS): cardiac features, management and short-term outcomes at a UK tertiary paediatric hospital SARS-CoV-2-related paediatric inflammatory multisystem syndrome, an epidemiological study. France Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort SARS-CoV-2 infection in children Characteristics and outcomes of children with coronavirus disease 2019 (COVID-19) infection admitted to us and canadian pediatric intensive care units Kawasaki disease: the role of immune complexes revisited Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities Neutrophil extracellular traps in COVID-19 Immunoglobulins in the treatment of COVID-19 infection: proceed with caution! Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations Not applicable. 1 PT and JLT conceptualized and wrote the editorial. Both authors read and approved the final manuscript. Ethics approval and consent to participate Not applicable. Not applicable. Both authors are Chief editor (JLT) and Associate editor (PT) of Annals of Intensive Care. Both authors declare that they have no other competing interest.